Cedazuridine
- Generic Name
- Cedazuridine
- Brand Names
- Inqovi 5 Tablet Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C9H14F2N2O5
- CAS Number
- 1141397-80-9
- Unique Ingredient Identifier
- 39IS23Q1EW
- Background
Myelodysplastic syndromes (MDS) are a group of hematopoietic neoplasms that give rise to variable cytopenias progressing to secondary acute myeloid leukemia (sAML), which is invariably fatal if untreated. Hypomethylating agents such as decitabine and azacitidine are used to treat MDS through inducing DNA hypomethylation and apoptosis of cancerous cells. Alth...
- Indication
Cedazuridine, in combination with decitabine, is indicated for the treatment of myelodysplastic syndromes (MDS), including MDS with refractory anemia, MDS with refractory anemia and ringed sideroblasts, MDS with refractory anemia and excess blasts, MDS scoring intermediate-1, intermediate-2, or high-risk on the International Prognostic Scoring System (IPSS),...
- Associated Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Associated Therapies
- -
Decitabine Plus Cedazuridine in TP53-Mutated MDS: Survival Compares Favorably With HMA
Decadine Demonstrates Therapeutic Potential for the Treatment of Myelofibrosis
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.